Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Verizon Communications Inc. (VZ)

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ICLR

MCRB

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Penang,,Malaysia,-,Feb,2,,2021:,Gamestop,Corp,Sign,Is

Intraday Update

Movers

AMSWA

AONC

ASNS

ASXC

BBCP

BGXX

BMEA

BNED

BRZE

CDXC

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CLEU

DOCU

FFIE

GERN

GRRR

LFLY

MAIA

MITQ

MLGO

NVAX

PRST

SCNI

SIFY

SMTC

SPWR

TPHS

UPST

VERO

VLCN

YEXT

Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

xr:d:DAFih-sWqhI:2,j:46865321670,t:23051015

AFIB

AFRM

ALAB

AMRC

AMRK

AOSL

APEI

ARKO

BROS

CLOV

CPNG

CRCT

CRUS

DTCK

ELAN

FLYW

GMED

Hannon Armstrong Sustainable Infrastructure Capital

HASI

INOD

INSP

ISUN

LAZR

LYFT

MASI

MXCT

MYGN

NIVF

PWSC

QLYS

REBN

RPTX

SATS

SHLS

SHOP

SIGA

SMLR

STAA

SWIM

TEVA

TIVC

TMCI

TOST

TRIP

TWLO

UBER

VECO

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Seres Therapeutics Inc

Health Care

General

Seres Therapeutics Received $50M Installment Payment Related To The Company's Previously Announced Sale Of Its Vowst Business To Société Des Produits Nestlé

<h3>Gainers</h3>
<ul>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) stock increased by 31.0% to $7.99 during Thursday's pre-market session. The market value of their outstanding shares is at $11.8 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 24.35% to $0.97. The market value of their outstanding shares is at $165.6 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 23.85% to $8.49. The company's market cap stands at $25.6 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares increased by 17.41% to $0.05. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock moved upwards by 14.56% to $0.49. The company's market cap stands at $3.4 million. </li>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares increased by 12.94% to $3.84. The company's market cap stands at $32.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares declined by 16.5% to $1.92 during Thursday's pre-market session. The company's market cap stands at $4.0 million. </li>
<li>Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) stock declined by 15.59% to $6.01. The company's market cap stands at $145.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock decreased by 15.39% to $1.32. The company's market cap stands at $2.1 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock fell 14.94% to $0.07. The market value of their outstanding shares is at $1.0 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock fell 11.85% to $2.68. The market value of their outstanding shares is at $4.7 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares declined by 10.93% to $0.39. The company's market cap stands at $19.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

AMIX

ARTV

CTXR

ERNA

GCTK

HEPA

MSPR

PRPO

SLXN

TRAW

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Following SER-155 administration, there was a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and a positive impact on biomarkers of systemic inflammation and immune homeostasis, in both cases as compared to placebo.

Biotech

Seres Therapeutics Announced New Translational Biomarker Results For Exploratory Endpoints From Its SER-155 Phase 1b Placebo-controlled Study In Patients Undergoing Allogenic Stem Cell Transplantation

WIIM

Seres Therapeutics shares are trading higher after the company announced that SER-155 received FDA breakthrough therapy designation for its bloodstream infection reduction.

Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) (Seres or the Company), a leading live biotherapeutics company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SER-155, the Company's lead investigational program, for the reduction of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies. In&nbsp;September 2024, Seres reported topline clinical data from Cohort 2 of its SER-155 Phase 1b placebo-controlled study in patients undergoing allo-HSCT, in which SER-155 was associated with a significant reduction in BSIs (77% relative risk reduction), a significant reduction in systemic antibiotic exposure, and lower incidence of febrile neutropenia, in each case as compared to placebo, through day 100 post-HSCT. Additionally, SER-155 was generally well tolerated, with no observed treatment-related serious adverse events.
FDA Breakthrough Therapy designation ensures communication and guidance from FDA to expedite the development of medicines which are intended to treat serious or life-threatening diseases, and in which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint over available therapies. The receipt of Breakthrough Therapy designation for SER-155, the Company's second program to receive such designation, grants Seres access to FDA senior management and a commitment from FDA to work closely with the Company, facilitating an efficient drug development process. In December 2023, SER-155 <a href="https://www.globenewswire.com/Tracker?data=6ctF6iOdNMFEAO4mU8cfdZ4pI6IUQ-05slSGi1GZR-krwnlLTUIXTNFHlfghiGOpxYH39ym-OTaUdO88CRjc3lYQY03IEXiEYqCwvYgqAYg3z3JRguywGQeKl5ZFHU-ZiPWnq9iPoK3U0JODzkeXzuYyF9lw8whlrm5tKRwuTU7pblQdB5wD2KRb4kcC_WtgeTF1cqc_GGOm25GVJZ87KG5OuGK2sMj1HRiTXcGZKE_Lu4OEJRe_t6ITy4utCZRC">received FDA Fast Track designation</a> for reducing the risk of infection and GvHD in this patient population.

Government

Regulations

Seres Therapeutics' SER-155 Receives FDA Breakthrough Therapy Designation for Bloodstream Infection Reduction

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $10 price target.

Price Target

Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $1.25 price target.

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.25) by 32 percent. This is a 3.13 percent decrease over losses of $(0.32) per share from the same period last year.

Earnings

Seres Therapeutics Q3 2024 GAAP EPS $(0.33) Misses $(0.25) Estimate, Seres Had $66.8M In Cash And Cash Equivalents, That Is Expected To Fund Operations Into The Fourth Quarter Of 2025

Comments

Seres Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga